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Abstract
Background: The combination of bevacizumab and irinotecan is a new chemotherapy protocol increasingly used for 
recurrent malignant glioma. Results from phase II trials suggest this drug combination is beneficial to patients, but no 
conclusive comparisons between this and other treatment protocols have been published.
Methods: We performed a systematic review and survival gain analysis of phase II studies to evaluate the efficacy and 
safety of bevacizumab plus irinotecan treatment. To do this, we utilized a preexisting database from which the mean 
overall survival and response rate of patients could be predicted. Survival gain, which characterized the influence of 
treatment, was defined as the difference between observed and predicted mean overall survival. Response gain was 
calculated similarly.
Results: 741 cohorts were enrolled in the database. Among them, 282 cohorts were based on recurrent adult HGG, 
mean reported median overall survival was 10.96 ± 8.4 months, and mean response rate was 18.9% ± 20.5. We found 
that compared with other treatment protocols, bevacizumab plus irinotecan largely improved response rates (P = 
0.00002) and had a possible moderate effect on overall survival time (P = 0.024). Hemorrhage, thromboembolic 
complications, and gastrointestinal toxicities were the most frequently reported side effects.
Conclusion: The combination of bevacizumab and irinotecan might improve outcome in patients with recurrent 
malignant glioma. Randomized controlled trials are recommended to evaluate this treatment protocol and the 
additional value of irinotecan.
Background
High-grade glioma (HGG), also named malignant glioma,
is the most common brain tumor in adults, and the out-
come of patients with HGG remains poor [1]. The stan-
dard of care for adult patients with glioblastoma is
radiation and temozolomide [2]. However, this regimen
yields median survival times of only 12 to 15 months for
patients with newly diagnosed glioblastomas and only 2
to 5 years for patients with newly diagnosed anaplastic
gliomas [3]. Once the tumors recur the prognosis is even
worse, with a median survival of only 3 to 9 months
regardless of the treatment regimen [4,5]. Very few evi-
dence-based treatment options are available for patients
with recurrent disease, and treatment response for glio-
blastoma has generally been less than 20%, with a 6-
month progression-free survival (PFS) rate of less than 9-
16% [4,6]. One of the difficulties in finding other effective
treatment regimens is the variability of outcome data in
HGG studies, which is, at least in part, caused by disease
heterogeneity and differing eligibility criteria [7,8].
Topoisomerase 1 inhibitors, such as irinotecan and
topotecan, provide a viable treatment option for tumors
resistant to temozolomide since the mechanisms of
action of these two classes of drugs and the known mech-
anisms of resistance do not overlap [9]. Irinotecan was
proved to have activity against non-glioma malignancies,
such as gastrointestinal malignancies [10]. It was also
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regarded as an alternative choice for recurrent HGG
despite the controversy regarding its ability to pass
through the blood brain barrier. However, as a single
agent, irinotecan showed disappointing results in the
treatment of recurrent malignant gliomas [11].
Bevacizumab, the humanized monoclonal antibody
against vascular endothelial growth factor (VEGF), has
been approved by the U. S. Food and Drug Administra-
tion (FDA) for the treatment of colorectal, lung, and
breast cancers. In May 2009, FDA has granted accelerated
approval for single bevacizumab for use in patients with
glioblastoma that has progressed despite previous ther-
apy . Bevacizumab has generally been used in combina-
tion with cytotoxic agents [12,13]. However, the value of
combining bevacizumab with irinotecan to treat HGG is
still unclear. The treatment response rates ranged from
28 to 86%, with a 6-month PFS ranging from 9.5 to 78.6%.
With this large variation in outcome data the question of
the effectiveness of this drug combination remains open.
Recently, a phase II study survival gain meta-analysis
was reported using novel mathematical methods to com-
pare different nitrosourea drugs [8]. Here we did a sys-
tematic review of published phase II trials of
bevacizumab plus irinotecan for recurrent HGG and
used the previous mathematical technology to analyze
the survival and response benefit of this treatment proto-
col.
Methods
Identification and selection of studies
This analysis was based upon a database that had been
created for a treatment arm summarizing analyses by
compiling information on HGGs from literature pub-
lished from 1976 to 2008. This database had been used
previously in comparing different nitrosourea drugs [7,8].
This method generally falls under the umbrella of meta-
analysis [14]. The preexisting database was expanded
through May 2008.
In order to address the question of our study a further
independent search was carried out by querying PubMed
(updated through September 2009), EMBASE (1980-Sep-
tember 2009), and Cochrane controlled-trials registry
databases using the search words "bevacizumab," "irino-
tecan," "CPT-11," "glioma," and "glioblastoma." No lan-
guage or date limitations were imposed. The following
selection criteria were applied: (1) Study population of
patients with histologically proven malignant glioma, all
of whom had experienced tumor progression that was
measurable on magnetic resonance imaging (MRI) and
received bevacizumab plus irinotecan as salvage chemo-
therapy; (2) Study contained information on the diagno-
sis of recurrent malignant glioma, treatment protocol,
criteria for response, responses to treatment, and overall
survival or PFS; (3) The response rates for recurrent
HGG were measured by two consecutive MRI scans and
the Macdonald criteria were used. The partial response
was regarded if the contrasted MRI showed more than
50% decrease in the area of enhancement and stable or
decreased T2 and FLAIR signal, with a stable or
decreased dose of corticosteroid and a stable or improved
clinical status. The complete response was determined by
the resolution of all measurable abnormalities on the con-
trast images, as well as by stable or decreased disease on
T2 and FLAIR images for any patient who was on a stable
or decreased corticosteroid dose and with stable and
improved clinical status. Disease progression was
regarded if there was more than 25% increase in the area
of enhancement, appearance of a new lesion, or deterio-
ration in the patient's clinical status that was thought to
be related to tumor progression. The patient was deemed
to be stable if the criteria for a partial or complete
response or tumor progression were not met and if there
was no disease progression. (4) In case of duplicate publi-
cation of the same patient cohort, only the most recent
publication was used for further analyses. The decision to
include a trial was made separately by two of our
researchers (Xu and Chen), who then compared their lists
and resolved any discrepancies.
Data extraction
As described previously, the analysis was based upon a
database. Briefly, patient cohorts were generated into a
database based on every published paper about HGG.
Each patient cohort included more than 30 parameters,
such as general characteristics (mean age, sex, etc.), path-
ological diagnosis, treatment response, and survival time.
If there was more than one group of patients included in
one paper, patient cohorts were generated separately
depending on the different groups. The median overall
survival time was recorded from each study. Other out-
come parameters and population characteristics were
analyzed in relation to median overall survival and then
used to calculate predicted median overall survival using
various multiple regression models; no treatment infor-
mation was used in calculating the predicted overall sur-
vival and response. Finally, the predicted median overall
survival was compared to the reported median overall
survival time and the difference was called "survival gain".
Response was quantified in the same way as overall sur-
vival. The influence on response of parameters character-
izing eligibility criteria and patient cohort was analyzed
and used to compute the predicted response rate (com-
plete response and partial response) of a given patient
cohort. The "response gain" was then compared between
groups.
To analyze the effect of the combination of irinotecan
and bevacizumab on median overall survival and treat-
ment response, comparisons were made between recur-Xu et al. BMC Cancer 2010, 10:252
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rent HGG patient cohorts treated with both drugs and
those treated with neither. Histograms were created for
visual comparison, and the Mann-Whitney U  test was
applied when appropriate.
A l l  a n a l y s e s  w e r e  d o n e  u s i n g  S P S S  s o f t w a r e ,  v e r s i o n
16.0. (SPSS Inc® Fulfillment center Haverhill MA, SPSS
16.0) and P < 0.05 was regarded as statistical significant.
Results
Overall survival of the database
The database contained 547 cohorts between 1973 and
2008 when it was used in last published paper, with a
mean reported median overall survival of all cohorts
being 13.7 months (standard deviation [SD], 11.7
months) [8]. Now that the database had been expanded
from 547 to 741 cohorts, the mean reported median over-
all survival time increased to 13.7 months (SD 11.1
months), and 1-year overall survival percentage was 18.9
± 21.1% (Fig. 1). Among the 741 cohorts, 282 cohorts
were based on recurrent adult HGG, with a mean of
median survival time of 10.96 months (SD 8.4 months).
Response rates of the database
Among the 326 cohorts that reported response rates, the
mean response rate was 23.3% (range 0-100; see Fig. 2 for
distribution). The response rate was significantly differ-
ent when patients with newly diagnosed HGG were com-
pared with patients with recurrent HGG (32.6% ± 23.4
versus 18.9% ± 20.5), when patients with glioblastoma
only were compared with patients with anaplastic astro-
cytoma (18.2% ± 17.2 versus 30.8% ± 24.9).
Figure 1 Observed median overall survival and percentage of 1-year overall survival for patients with malignant glioma in all published 
data. These data showed a median overall survival time of 13.7 ± 11.1 months and 1-year overall survival percentage of 18.9 ± 21.1% for malignant 
glioma patients.
Figure 2 Distribution of treatment response rates for patients 
with malignant glioma in all published data. The mean response 
rate was 23.3 ± 22.3% in 326 studies.Xu et al. BMC Cancer 2010, 10:252
http://www.biomedcentral.com/1471-2407/10/252
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Description of studies with irinotecan and bevacizumab
A total of 12 studies met all our inclusion criteria, and 10
of the 12 studies were enrolled in the survival gain-analy-
sis [15-24]. The other two studies were excluded because
of duplicate patient cohorts [25,26]. The basic character-
istics of the enrolled cohorts are described in Table 1, and
the treatment response is listed in Table 2.
411 patients were included in our analysis. The median
progression-free survival time ranged from 2.4 to 13.4
months, the median overall survival time ranged from 6.2
to 14.9 months, with response rates ranging from 28% to
86%. Different doses of bevacizumab were used in these
studies, but most patients received 10 mg/kg, while some
other patients received 5 mg/kg, 5 mg/m2 and 15 mg/kg.
The dose of irinotecan was mainly stable; most patients
Table 1: Basic characteristics of enrolled studies
Study No. Gender (n) Median 
age (year)
Histology (n) Treatment
Male Female WHO IV WHO III
Chen [15] 21 11 10 58 17 4 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) every other week
Vredenburgh[16] 35 22 13 48 35 0 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) Q14d, beva (15 mg/kg) Q21d + irino (340 
mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 
1,8,22, and 29, on a 6-week cycle
Bokstein [17] 20 14 6 56 17 3 Beva (5 mg/kg) + irino (125 mg/m2) every other week
Guiu [18] 77 50 27 52 49 28 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED)
Ali [19] 13 7 6 53 13 0 Beva (5 mg/m2) every 2 weeks + irino (125 mg/m2) every 
week for 3 weeks with 1 week off; beva (10 mg/m2) + irino 
(125-250 mg/m2) every 2 weeks
Desjardins [20] 33 22 11 43 0 33 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) Q14d, beva (15 mg/kg) Q21d + irino (340 
mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 
1,8,22, and 29, on a 6-week cycle
Kang [21] 27 NR NR 46 12 15 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) on days 1 and 15 every 28 days
Poulsen [22] 52 34 18 46 28 24 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) every 2 weeks
Zuniga cohort A 
[23]
14 9 5 51 0 14 Beva (10 mg/kg) IV on days 1,15,29 for each cycle; irino 
(340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 
weeks, on a 6-week cycle
Zuniga cohort B 
[23]
37 24 13 53 37 0 Beva (10 mg/kg) IV on days 1,15,29 for each cycle; irino 
(340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 
weeks, on a 6-week cycle
Friedman [24] 82 57 25 57 82 0 Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 
for non-EIAED) every 2 weeks
No. number of patients, Beva bevacizumab, Irino irinotecan, EIAED enzyme-inducing antiepileptic drugs, Q14d every 14 days, Q21d every 21daysXu et al. BMC Cancer 2010, 10:252
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received 340 mg/m2 for those who take enzyme-inducing
antiepileptic drugs (EIAED) or 125 mg/m2 for those with
non-EIAED. In each cohort there was no statistical differ-
ence between the results of patients receiving EIAED or
non-EIAED patients. Similarly, in all included studies
there were no statistical differences between the results
for patients receiving different cycles of bevacizumab
plus irinotecan.
Toxicity
Toxicity and side effects of bevacizumab plus irinotecan
for patients with recurrent malignant glioma are listed in
Table 3. Hemorrhage, thromboembolic complications
(e.g., thrombotic thrombocytopenic purpura, deep
venous thrombosis, pulmonary embolism, myocardial
infarction), and gastrointestinal toxicities (e.g., diarrhea,
gastrointestinal perforation) were most frequently
reported. Further side effects included renal dysfunction
(proteinuria, hematuria), fatigue, and neutropenia.
Comparing bevacizumab plus irinotecan outcome with 
other HGG data
We compared the response gain and survival gain of
recurrent HGG patients between the bevacizumab plus
irinotecan cohorts (combination cohorts) and other
treatment cohorts (control cohorts) using the Mann-
Whitney U test.
We first compared the response gain of recurrent HGG
patients treated with the combination protocol to those
treated with other protocols and there was a clear result
in favor of the novel drug combination: the mean rank of
186 control cohorts was 94.31, while the mean rank of 10
bevacizumab plus irinotecan cohorts was 178.27 (P =
0.00002). These results showed that the improved
response rate after treatment with the combination of iri-
notecan and bevacizumab was highly statistically signifi-
cant. The response gain distributions of the two groups
are shown in Fig. 3.
We then tested the survival gain between recurrent
HGG patients treated with bevacizumab plus irinotecan
and those treated with other protocols. The Mann-Whit-
ney U test showed that the mean rank of the 11 combina-
tion cohorts was 181.36, while the mean rank of 250
recurrent control cohorts was 128.78 (P = 0.024). The
survival gain distributions of the two groups are shown in
Fig. 4. There was an attempt to determine PFS as an addi-
tional endpoint, but because it was reported only rarely in
Table 2: Treatment response of bevacizumab plus irinotecan for patients with recurrent malignant glioma
Study mPFS PFS 6-month (%) mOS OS 6-month Response rate (%) Survival gain Response gain
Chen [15] 2.4 9.5 8.5 61.9 38 4.23 21.37
Vredenburgh [16] 5.5 46 9.6 77 57 5.07 42.18
Bokstein [17] 4.2 25 7 55 47 0.73 31.02
Guiu [18] NR NR NR NR 36 -7.91 22.72
Ali [19] 5.5 46.2 6.2 53.85 77 2.81 61.96
Desjardins [20] 6.9 55 14.9 79 61 4.27 36.38
Kang [21] 5.1 45.8 12.6 84 44 2.94 24.34
Poulsen [22] 5 32.4 6.9 NR 28 -0.65 8.24
Zuniga Cohort A [23] 13.4 78.6 NR 85.7 86 12.6 61.49
Zuniga Cohort B [23] 7.6 63.7 11.5 78 76 6.72 60.71
Friedman [24] 5.6 50.5 8.7 NR 37.8 1.24 22.84
mPFS median progression-free survival, mOS median overall survival
Response rate (%) = complete response (%) + partial response (%)
NR = not reportedXu et al. BMC Cancer 2010, 10:252
http://www.biomedcentral.com/1471-2407/10/252
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the past the data of the control group were insufficient for
the comparison (data not shown). In summary these
results suggest that combination of bevacizumab and iri-
notecan can provide additional survival benefit compared
to other treatment protocols in recurrent HGG patients.
Discussion
The efficacy of bevacizumab plus irinotecan for recurrent
malignant glioma has been evaluated in several clinical
trials in recent years. However, the differences in patient
characteristics made it difficult to judge the outcome
results. Thus, we carried out a meta-analysis of the avail-
able evidence from phase II trials in order to more pre-
cisely define the efficacy of the combination. We found
the treatment protocol might improve both the response
rate and survival time for patients with recurrent malig-
nant glioma, results that were consistent with the experi-
ence of others.
Response rate and overall survival are considered the
two most important parameters in assessing the efficacy
of any treatment protocol, yet one of the two is necessar-
ily only a surrogate parameter. It is anticipated that treat-
ment protocols that result in higher response rates will
also result in higher survival rates in following phase III
studies. In our analysis, the benefit of the drug combina-
tion appeared large when considering response, while the
effect on overall survival was only marginal. However,
response may translate directly into quality of life, and the
fact that the two endpoints did not correlate strongly sup-
ports the concept that the response rate is an important
additional parameter in evaluating efficacy of treatment
protocols.
Anti-angiogenic treatment has been promising in the
treatment of recurrent malignant gliomas [27,28]; so the
Progression Free Survival time (PFS) was regarded as
another important parameter for assessing efficacy of
Table 3: Toxicity of bevacizumab plus irinotecan for patients with recurrent malignant glioma
Study Number of patients Toxicity or side effects
Chen [15] 21 Not reported
Vredenburgh [16] 35 Thromboembolic complications (n = 4), Grade II proteinuria (n = 2), Grade II fatigue and withdrew 
consent(n = 4), Grade III or worse gastrointestinal toxicity (n = 4), Sepsis (n = 1), central nervous 
system hemorrhage (n = 1), leg ulcers (n = 1)
Bokstein [17] 20 Grade I hypertension (n = 1), Grade I rash (n = 1), Grade I and III fatigue (n = 3), Grade II epistaxis (n 
= 1), Grade II anemia (n = 1), Grade II diarrhea (n = 2), Grade II seizures (n = 1), Grade III paranoid 
psychosis (n = 1)
Guiu [18] 77 Intratumoral hemorrhage (n = 5, with spontaneous regression in 3) and thromboembolic 
complications including venous thrombophlebitis (n = 4), pulmonary embolism (n = 2), and 
myocardial infarction (n = 1); Grade III-IV hepatotoxicity (n = 2), reversible leukoencephalopathy 
(n = 1).
Ali [19] 13 Intracranial bleeding (n = 2), deep venous thrombosis (n = 1)
Desjardins [20] 33 Dose reduction due to gastrointestinal toxicity or neutropenia (n = 5), withdrew consent due to 
fatigue or gastrointestinal toxicity (n = 4), central nervous system hemorrhage (n = 1), thrombotic 
thrombocytopenic purpura (n = 1)
Kang [21] 27 Thromboembolic complications (n = 5), hemorrhage (n = 3), hematuria (n = 1), infection (n = 1), 
fatigue (n = 1), cough (n = 1), failure to thrive (n = 1)
Poulsen [22] 52 Grade III cerebral hemorrhage (n = 1), cardiac arrhythmia (atrial fibrillation), intestinal perforation 
(n = 1), superficial venous thrombosis (n = 1), hypertension (n = 3), neutropenia (n = 1), infection 
(n = 2), proteinuria (n = 1); Grade V diarrhea (n = 1)
Zuniga cohort A 
[23]
14 Grade II-III hypertension (n = 13), Grade I-II 
bleeding (n = 9)
____
Zuniga cohort B 
[23]
37 Grade III proteinuria-renal failure (n = 1), gastrointestinal perforation (n = 1), severe nausea/
vomiting (n = 4)
Friedman [24] 79 Hypertension (n = 21; Grade≥3 hypertension: n = 1); Hemorrhage, overall (n = 32; Grade≥3: n = 2); 
Hemorrhage, intracranial (n = 3; Grade≥3: n = 1); Wound-healing complications (n = 2; Grade≥3: n 
= 1); Venous thromboembolism (n = 8; Grade≥3: n = 7); Arterial thromboembolism (n = 5, 
Grade≥3: n = 2); Proteinuria (n = 2; Grade≥3: n = 1); Gastrointestinal perforation (n = 2; Grade≥3: n 
= 2); Reversible posterior leukoencephalopathy syndrome (n = 1, Grade≥3: n = 0); Aphasia 
(Grade≥3: n = 6); Confusional state (Grade≥3: n = 4); Convulsion (Grade≥3: n = 11); Diarrhea 
(Grade≥3: n = 4); Fatigue (Grade≥3: n = 7); Pneumonia (Grade≥3: n = 4); Pyramidal tract syndrome 
(Grade≥3: n = 4); Somnolence (Grade≥3: n = 4); Hypokalemia (Grade≥3: n = 6); Leukopenia 
(Grade≥3: n = 5); Lympyhopenia (Grade≥3: n = 6); Neutropenia (Grade≥3: n = 7)Xu et al. BMC Cancer 2010, 10:252
http://www.biomedcentral.com/1471-2407/10/252
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Figure 3 Response gain distribution in control group (a) and bevacizumab plus irinotecan group (b). The combination of bevacizumab and 
irinotecan showed benefit in treatment response for patients with recurrent HGG.
Figure 4 Survival gain distribution in control group (a) and bevacizumab plus irinotecan group (b). The combination of bevacizumab and iri-
notecan showed benefit in survival time for patients with recurrent HGG.Xu et al. BMC Cancer 2010, 10:252
http://www.biomedcentral.com/1471-2407/10/252
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treatment protocols. However, a recent study carried out
by Norden et al. found that PFS might not be an optimal
endpoint for anti-angiogenic treatment [29] because the
use of contrast-enhancement MRI may overestimate the
response rates [30]. Anti-VEGF treatment can reduce
vascular permeability, which can also account for the
radiographic improvement; this may not necessarily
reflect tumor cell death [31]. Decreased enhancement
could be because of both tumor cell death and the anti-
VEGF effect; thus, a more precise radiological measure-
ment for treatment response is needed. Chen et al [15]
reported  18F-fluorothymidine PET scanning could be
used as an imaging biomarker to predict overall survival
in patients with recurrent gliomas who are treated with
the combined bevacizumab and irinotecan protocol.
Other possibilities for measuring response include the
entire FLAIR signal abnormality in T2 weighted MRIs or
nuclear medicine methods such as thallium [32], amino
acids [33], or glucose [34]. However, even with these mea-
surements, the clinical relevance of these findings still
remains a question.
Our finding that the response rate of an anti-angiogenic
treatment may result in additional survival benefit is con-
sistent with previous phase II studies. However, Norden
et al. found that, compared to cytotoxic agents, anti-
angiogenic therapy may fail to prolong overall survival in
patients with recurrent malignant glioma [29]. It is also
noteworthy that, according to the discrepancies between
PFS and overall survival benefits, most patients died soon
after disease progression when bevacizumab failed indi-
cating that heavily pretreated patients may develop
VEGF-independent mechanisms of progression and must
be closely monitored [29].
The role of irinotecan in the treatment regimen has
been argued [35]. Single agent irinotecan used to treat
patients with recurrent malignant glioma did not show
good results [11,36]. When irinotecan was added to beva-
cizumab response rates and overall survival seemed to
improve in phase II trials. The reason for this is still
unclear; one possibility is that the use of bevacizumab
could decrease interstitial pressure, improve tissue oxy-
genation, and increase delivery of irinotecan to the tumor
[37,38]. However, a recent study showed that adding iri-
notecan to bevacizumab did not result in additional
improvement in overall survival time when compared
with single-agent bevacizumab (overall survival, 8.9
months for combination and 9.7 months for single-agent)
[39]. In our study, we did not compare survival gain and
response gain between single-agent and combined treat-
ment because of insufficient data for patients with recur-
rent malignant glioma treated with single-agent
bevacizumab. Further prospective studies may provide
more evidence to determine the additional role of irinote-
can in the treatment of recurrent malignant glioma.
The toxicity of this treatment protocol should also be
considered. In several meta-analyses, bevacizumab was
reported to be associated with many side-effects, includ-
ing venous thromboembolism [40], bleeding [41] and
gastrointestinal perforation [42]. According to the clinical
studies, hemorrhage, thromboembolic complications and
gastrointestinal toxicities were most frequently reported
(Table 3). The dose of bevacizumab may be related to vas-
cular complications. In our analysis, compared with most
studies that used the dose of 10 mg/m2 for bevacizumab,
Bokstein et al. used a dose of 5 mg/kg, which resulted in
significantly lower vascular complication rates [17]. The
gastrointestinal side effects were mainly due to irinote-
can; these side effects may decrease the quality of life in
these patients [43] and may even cause death [22].
The drug combination of irinotecan and bevacizumab
resulted in responses on radiological imaging which can
translate into increased survival. Also, this drug combina-
tion had some moderate toxicity. The question of
whether the benefits of the drug combination outweighs
the loss of quality of life caused by drug toxicity should be
considered by each patient, and our analysis might help
the doctors and patients to make a better decision.
Our study also had some limitations. First, all included
studies were phase II studies. Thus, it might bring great
heterogeneity because of the lack of control groups.
Although patients who received other treatment proto-
cols were set as control groups in this analysis, we still
cannot draw a firm conclusion with these data. Larger
phase III randomized controlled studies comparing beva-
cizumab plus irinotecan with other treatment protocols
are warranted so that the efficacy can be assessed prop-
erly. Second, the difference of survival gain between
groups (p value of 0.024) might be due to chance,
although it was statistically significant. Compared with a
p value of 0.00002 in response gain, it made us question
whether the improved response really translated into a
survival benefit for patients. Larger studies may be
needed to answer this question. Third, we did not include
the PFS-gain because of insufficient data. Although the
role of PFS in anti-angiogenic treatment is still not clear,
it is a very important parameter to assess the efficacy of
treatment protocols. It was used as an endpoint in all 11
bevacizumab plus irinotecan cohorts of 10 studies. How-
ever, it was not used widely in early studies, and conse-
quently cannot be calculated at the present time. Further
analysis with more data might be helpful in this field.
Conclusions
Our systematic review and survival gain analysis of phase
II studies showed the drug combination of bevacizumab
and irinotecan might improve overall survival and
response rate in patients with HGG. Future randomized
studies are warranted to evaluate this treatment protocolXu et al. BMC Cancer 2010, 10:252
http://www.biomedcentral.com/1471-2407/10/252
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more precisely; the additional value of irinotecan as an
addition to bevacizumab should also be considered in
such studies.
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